CEL-SCI reaches full enrollment in pivotal Phase 3 head and neck cancer study.
No further patient enrollment is required in the pivotal Phase 3 head and neck cancer study by CEL-SCI Corporation for its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection). The accrual and treatment phases of the Phase 3 study are complete. All of the 928 enrolled patients in the study are being followed-up as required by the study protocol, according to the company.
CEL-SCI recently announced that the study’s Independent Data Monitoring Committee (IDMC) completed its most recent review of the data from all 928 patients enrolled in the study, and recommended continuing the study as there was no evidence of any significant safety questions.
The primary endpoint of the study, a 10 percent improvement in overall survival of the Multikine treatment regimen plus Standard of Care (SOC) vs. Standard of Care alone, will be determined after a total of 298 deaths have occurred in these two main comparator arms of the study and have been recorded in the study database.
The last patient was enrolled in the study in September 2016. Approximately 135 patients were enrolled in the study from 2011 to 2013, about 195 were enrolled in 2014, about 340 in 2015, and about 260 in 2016. The study protocol assumed an overall survival rate of about 55 percenet at 3 years for the SOC treatment group alone.
IDMCs are committees commonly used by sponsors of clinical trials to protect the interests of the patients and the integrity of the study data in ongoing trials, especially when the trials involve patients with life threatening diseases, and when, as in cancer clinical trials, they extend over long periods of time.
(Source: CEL-SCI Corporation)
Filed Under: Drug Discovery